$161,250
median · per year, annualized USD
$98,614
median · per year, annualized USD
Senior Computational Biologist – Early Discovery Immunology
Senior Computational Biologist - Early Discovery Oncology
Associate Principal Computational Biologist, Neuroscience
Computational Biologist II, CellxState
Computational Biologist
Staff Computational Biologist
Senior Biologist and Project Manager
Computational Biologist
Plant Synthetic Biologist
Associate Synthetic Biologist
Care Management Pharmacist
Lead Compounding Pharmacist - Romeoville, IL
Compliance Pharmacist, Dispense & Fulfillment
Pharmacist In Charge (Specialty) - Lufkin, TX
Pediatric Clinical Pharmacist
Pharmacist
Superintendent Pharmacist
Per Diem Pharmacist, Strut
Clinical Pharmacist
Fulfillment Pharmacist - Torrance, CA
| Company | Median | Roles |
|---|---|---|
Recursion
|
$193,820 | 3 |
Biohub
|
$164,025 | 2 |
OXMAN
|
$122,500 | 2 |
| VH Valo Health | $180,375 | 1 |
NewLimit
|
$175,000 | 1 |
Environmental Science Associates
|
$147,500 | 1 |
Axle
|
$79,000 | 1 |
California Academy of Sciences
|
$57,491 | 1 |
| Company | Median | Roles |
|---|---|---|
| PH Pulse Healthcare | $97,225 | 16 |
Montu UK
|
$87,536 | 11 |
| SH Shields Health Solutions | $125,000 | 5 |
Hims & Hers
|
$130,000 | 4 |
Felix
|
$76,397 | 4 |
Ro
|
$137,998 | 3 |
House Rx
|
$135,000 | 3 |
Pharmacy2U
|
$75,277 | 3 |
| Location | Median | Roles |
|---|---|---|
| New York | $193,820 | 3 |
| San Francisco | $175,000 | 3 |
| Location | Median | Roles |
|---|---|---|
| London | $94,064 | 18 |
The median for Biologist is $161,250 per year (typically $126,500–$184,618), versus $98,614 for Pharmacist ($82,252–$127,920). That puts Biologist about 64% ahead at the median.
Both figures are computed live from active listings on JobsRadar and normalized to annualized USD, so Biologist and Pharmacist are compared on equal terms regardless of the currency each role was originally posted in. Only roles that publish a salary range feed the medians; numbers refresh every few hours as new roles post and older ones close, so this comparison reflects the market right now rather than a fixed survey. Use it as a directional benchmark when weighing one path against the other.